Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review

被引:23
|
作者
Timmins, Hannah C. [1 ]
Mizrahi, David [2 ]
Li, Tiffany [1 ]
Kiernan, Matthew C. [1 ,3 ,4 ]
Goldstein, David [2 ,5 ]
Park, Susanna B. [1 ]
机构
[1] Univ Sydney, Fac Med & Hlth, Brain & Mind Ctr, Sydney, NSW, Australia
[2] UNSW Sydney, Fac Med, Prince Wales Clin Sch, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Royal Prince Alfred Hosp, Camperdown, NSW, Australia
[5] Prince Wales Hosp, Dept Med Oncol, Randwick, NSW, Australia
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
Chemotherapy; Neuropathy; Risk factors; Obesity; Diabetes; Physical activity; QUALITY-OF-LIFE; CANCER-PATIENTS; COLORECTAL-CANCER; PHYSICAL-ACTIVITY; BREAST-CANCER; SENSORY NEUROPATHY; BODY-MASS; EXERCISE; SURVIVORS; WOMEN;
D O I
10.1007/s11764-021-00988-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common dose-limiting toxicity of cancer treatment causing functional impairment and impacting quality of life. Effective prevention and treatment of CIPN are lacking, and CIPN risk factors remain ill-defined. Metabolic syndrome and associated conditions have emerged as potential risk factors, due to their high prevalence and independent association with nerve dysfunction. This systematic review aimed to investigate the association between these common metabolic-lifestyle factors and CIPN. Methods Searches were undertaken using Medline, Embase, CINAHL, Scopus, and Web of Science databases, with additional studies identified from bibliographic references cited by original and review articles. Articles that analyzed metabolic-lifestyle risk factors associated with CIPN for patients treated with platinum- or taxane-based chemotherapy were included. Results Searches identified 6897 titles; 44 articles had full text review, with 26 studies included. Overall incidence of neuropathy ranged from 16.9 to 89.4%. Obesity had the most consistent patient-oriented evidence as a risk factor for CIPN, with moderate evidence suggesting diabetes did not increase CIPN incidence or severity. A limited number of studies supported an association with low physical activity and greater CIPN risk. Conclusions Comorbidities and lifestyle factors, particularly obesity and low physical activity, may contribute to the development of CIPN. The implementation of sensitive outcome measures in large-scale clinical trials is required to further elucidate CIPN risk factors and evaluate if changes in lifestyle would improve long-term CIPN outcomes for cancer survivors. Implications for Cancer Survivors Better understanding of CIPN risk profiles may inform personalized medicine strategies and help elucidate pathophysiological mechanisms which could be targeted for neuroprotection.
引用
收藏
页码:222 / 236
页数:15
相关论文
共 50 条
  • [41] Chemotherapy-Induced Peripheral Neuropathy: A Current Review
    Staff, Nathan P.
    Grisold, Anna
    Grisold, Wolfgang
    Windebank, Anthony J.
    ANNALS OF NEUROLOGY, 2017, 81 (06) : 772 - 781
  • [42] The Efficacy of Acupuncture in Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Meta-Analysis
    Chien, Tsai-Ju
    Liu, Chia-Yu
    Fang, Ching-Ju
    Kuo, Chun-Yu
    INTEGRATIVE CANCER THERAPIES, 2019, 18
  • [43] Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer
    van Velzen, Merel J. M.
    Pape, Marieke
    Sprangers, Mirjam A. G.
    van Kleef, Jessy Joy
    Mostert, Bianca
    Beerepoot, Laurens, V
    Slingerland, Marije
    Gootjes, Elske C.
    Hoekstra, Ronald
    van de Poll-franse, Lonneke, V
    Mohammad, Nadia Haj
    van Laarhoven, Hanneke W. M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (07): : 455 - 461
  • [44] Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis
    Hoshino, Nobuaki
    Ganeko, Riki
    Hida, Koya
    Sakai, Yoshiharu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 434 - 442
  • [45] Peripheral neuropathy and lifestyle factors in women with breast cancer receiving taxane-based chemotherapy: Pathway analysis
    Ellikci, Rabia
    Arslan, Selda
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2023, 66
  • [46] Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy
    Bakogeorgos, Marios
    Georgoulias, Vassilis
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (11) : 1045 - 1060
  • [47] Chemotherapy-induced peripheral neuropathy and its determinants among adult cancer patients on chemotherapy in northwest Ethiopia oncology centers, 2022
    Habtie, Tesfaye Engdaw
    Abate, Melsew Dagne
    Abebe, Gebremeskel Kibret
    Wolie, Zenaw Tessema
    Alamaw, Addis Wondmagegn
    Mitiku, Haymanot Zeleke
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [48] Profiles of chemotherapy-induced peripheral neuropathy in breast cancer patients undergoing taxane-based chemotherapy: A latent class analysis
    Li, Ruo-lin
    Bai, Li-xiao
    Liu, Yu
    Yang, Ai-ling
    Chen, Lu
    Zhao, Fu-yun
    Zhang, Ling
    Liu, Jun-E
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2025, 74
  • [49] Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review and Proposed Theoretical Model
    Lee, Kimberley T.
    Bulls, Hailey W.
    Hoogland, Aasha I.
    James, Brian W.
    Colon-Echevarria, Claudia B.
    Jim, Heather S. L.
    CANCERS, 2024, 16 (14)
  • [50] Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review
    Mols, Floortje
    Beijers, Tonneke
    Vreugdenhil, Gerard
    van de Poll-Franse, Lonneke
    SUPPORTIVE CARE IN CANCER, 2014, 22 (08) : 2261 - 2269